Skip to main content

Advertisement

Log in

Rheumatic manifestations of current pharmacopeia

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Patient complaints arising as manifestations of medication side effects are commonly encountered in clinical practice. A rheumatologist must routinely consider side effects of drugs in the differential diagnosis of many symptoms. This review will remind the reader of certain well-described and some newly reported side effects commonly encountered in an internal medicine practice. Focal points incude arthralgias/arthritis, myopathy/myositis, ANA/drug-induced lupus, bone loss/osteoporosis, and tendon rupture.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References and Recommended Reading

  1. Nesher G, Zuckner J.: Rheumatologic complications of vitamin A and retinoids. Semin Arthritis Rheum 1995, 24:291–296.

    Article  PubMed  CAS  Google Scholar 

  2. Bewley AD, et al.: Isotretinoin causing aseptic arthropathy. Clin Exp Dermatol 1995, 20:279.

    Article  PubMed  CAS  Google Scholar 

  3. Carey BM, Parkin GJ, Cunliffe WJ, et al.: Skeletal toxicity with isotretinoin therapy: a clinico-radiographic evaluation. Br J Dermatol 1988, 119:609–614.

    Article  PubMed  CAS  Google Scholar 

  4. Anonymous: Adverse events following hepatitis B immunization. Aust Adv Drug React Bull 1996, 15:6.

    Google Scholar 

  5. Weibel RF, Benor DE: Chronic arthropathy and musculoskeletal symptoms associated with rubella vaccines: a review of 124 claims submitted to the National Vaccine Injury Compensation Program. Arthritis Rheum 1996, 39:1529–1534.

    Article  PubMed  CAS  Google Scholar 

  6. Berning SE, et al.: Adverse events associated with high dose Rifabutin in macrolide-containing regimens for the treatment of MAI complex lung disease. Clin Infectious Disease 1996, 22:885.

    CAS  Google Scholar 

  7. Knights SE, Leandro MJ, Khamashta MA, Hughes GR: Minocycline-induced arthritis. Clinical Exp Rheum 1998, 16:587–590.

    CAS  Google Scholar 

  8. Loeuille D, Gillet P, Netter P: Fluoroquinolone-induced arthralgia and MRI. J Rheumatol 1996, 23:1313–1314.

    PubMed  CAS  Google Scholar 

  9. Bajaj S, Bell MJ, Shumak S, Briones-Urbina R: Antithyroid arthritis syndrome. J Rheumatol 1998, 25:1235–1239.

    PubMed  CAS  Google Scholar 

  10. Tosun M, Guler M, Erem C, et al.: Intermittant polyarthritis due to PTU. Clin Rheumatol 1995, 14(5):574–575.

    Article  PubMed  CAS  Google Scholar 

  11. Meier CR, Jick H: Omeprazole, H2 blockers, and polyarthralgias: case-control study. BMJ 1997, 315:1283.

    PubMed  CAS  Google Scholar 

  12. Plotz PH, et al.: Current concepts in the idiopathic inflammatory myopathies: polymyositis, dermatomyositis, and related disorders. Ann Intern Med 1989, 111(2):143–157.

    PubMed  CAS  Google Scholar 

  13. England, HDF, et al.: Mitochondrial myopathy developing on treatment with the HMG CoA reductase inhibitors: simvastatin and pravastatin. Aust NZ J Med 1995, 25:374–375.

    CAS  Google Scholar 

  14. Jonas GB: Increased incidence of myositis in patients treated with high dose simvastatin. Am J of Cardiol 1998, 81(2):259.

    Article  Google Scholar 

  15. Horn, M: Coadministration of itraconazole with hypolipidemic agents may induce rhabdomylysis in healthy individuals. Arch Dermatol 1996, 132:1254.

    Article  PubMed  CAS  Google Scholar 

  16. Neuronen PJ, et al.: Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Therapy 1996, 60:54–61.

    Article  Google Scholar 

  17. Jacobson RH, Wang P, Glueck CJ: Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone. JAMA 1997, 227(4):296.

    Article  Google Scholar 

  18. Chariot, et al.: Cytochrome C oxidase deficiency in zidovudine myopathy affects perifascular muscle fibers and arterial smooth muscle cells. Neuropathol Appl Neurobiol 1995, 21:540–547.

    PubMed  CAS  Google Scholar 

  19. Sinnwell, TM, et al.: Metabolic abnormalities in skeletal muscle of patients receiving zidovudine therapy observed by 31P in vivo magnetic resonance spectroscopy. J Clin Invest 1995, 96:126–131.

    Article  PubMed  CAS  Google Scholar 

  20. Dienstag JL, et al.: A preliminary trial of lamivudine for chronic hepatitis B infection. N Eng J Med 1995, 333:1657–1661.

    Article  CAS  Google Scholar 

  21. Finger DR, Plotz PH, Heywood G: Myositis following treatment with high dose IL-2 for malignancy. J Rheum 1994, 21(4):752–753.

    Google Scholar 

  22. Alloway JA, Salata MP: Quinidine-induced rheumatic syndromes. Semin Arthritis Rheum 1995, April, (5):315–322.

    Article  Google Scholar 

  23. Hess E: Drug-related Lupus. N Engl J Med 1988, 11(22):1460–1462.

    Article  Google Scholar 

  24. Yung R, Chang S, Hemati N, et al.: Mechanisms of druginduced lupus: IV. Comparison of procainamide and hydralazine with analogs in vitro and in vivo. Arthritis Rheum 1997, 40(8):1436–1443.

    Article  PubMed  CAS  Google Scholar 

  25. Masson C, Chevailler A, Pascaretti C, et al.: Minocycline related lupus. J Rheum 1996, 23:2160–2161.

    PubMed  CAS  Google Scholar 

  26. Uzzan B, Campos J, Cucherat M, et al.: Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab 1996, 81(12):4278–4289.

    Article  PubMed  CAS  Google Scholar 

  27. Schneider DL, et al.: Thyroid hormone use and bone mineral density in elderly women: effect of estrogen. JAMA 1994, 271:1245–1249.

    Article  PubMed  CAS  Google Scholar 

  28. Struijs A, Mulder H: The effects of inhaled glucocorticoids on bone mass and biochemical markers of bone homeostasis: a 1-year study of beclomethasone vs. budesonide. Netherlands J Med 1997, 50:233–237.

    Article  CAS  Google Scholar 

  29. Anonymous: ommendations for the prevention and treatment of glucocorticoid-induced osteoporosis Arthritis Rheum 1996 39(11):1791–1801.

  30. Adachi JD, et al.: Vitamin D and calcium in the prevention of corticosteroid-induced osteoporosis: a 3-year follow-up. J Rheumatol 1996, 23:995–1000.

    PubMed  CAS  Google Scholar 

  31. Eastell R, on behalf of UK Consensus Group Meeting on Osteoporosis Management of Corticosteroid Induced Osteoporosis: J Intern Med 1995, 237:419–447.

    Article  Google Scholar 

  32. Saag HG, Emkey R, Schnitzer TJ, et al.: Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis: Glucocorticoid-induced Osteoporosis Intervention Study Group. N Engl J Med 1998, 339:292–299.

    Article  PubMed  CAS  Google Scholar 

  33. Sivakumaran M, Ghosh K, Zaidi Y, Hutchinson RM:Osteoporosis and vertebral collapse following low-dose LMWH therapy in a young patient. Clin Lab Hematol 1996, 18:55–57.

    Article  CAS  Google Scholar 

  34. Nightingale, SL: From the Food and Drug Administration. JAMA 1996, 276:774.

    Article  PubMed  CAS  Google Scholar 

  35. Pai VS: Rupture of the plantar fascia. J Foot Ankle Surg 1996, 35:9–40.

    Article  Google Scholar 

  36. Aronson JK: Side Effects of Drugs Annual 20 1997. UK:Elsevier Publishers; 1997.

    Google Scholar 

  37. Aronson JK. Side Effects of Drugs Annual 21 1998. UK:Elsevier Publishers; 1998.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brenner, J., Solitar, B.M. & Golden, B.D. Rheumatic manifestations of current pharmacopeia. Curr Rheumatol Rep 2, 151–155 (2000). https://doi.org/10.1007/s11926-000-0055-1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-000-0055-1

Keywords

Navigation